01
概述
Vesugen为Khavinson肽体系中的三肽Lys-Glu-Asp（KED），针对血管壁与内皮细胞研究。
02
药理与机制
调节内皮细胞基因表达，与血管稳态、内皮功能相关因子的转录调控有关。
03
研究方向
R.01
血管基质生物调节三肽
血管老化、内皮功能与血管基质生物学研究中的工具分子。
04
结构信息
三肽Lys-Glu-Asp。
氨基酸序列
Lys-Glu-Asp
仅供科研用途。不构成医疗建议，不用于诊断或治疗。
← 返回列表条目 · LZH-016
lyophilized
KED · 血管研究
Vesugen
血管基质生物调节三肽
技术数据LZH-016
- 代号
- KED
- 半衰期
- Short plasma; transcriptional effects persist
- 研究给药途径
- SC / sublingual (research)
- 分子靶点
- Endothelial gene expression modulation
- 发现 / 披露
- Khavinson group, 2000s
- 目标纯度
- ≥ 98%
- 建议储存
- −20°C 避光，复溶后 2~8°C
别名
KED tripeptide
外观
White lyophilized powder
溶解性
Water soluble
氨基酸序列
Lys-Glu-Asp
FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.
FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.